nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—SLC22A3—Progesterone—uterine cancer	0.157	0.23	CbGbCtD
Imipramine—SLC22A2—Progesterone—uterine cancer	0.0928	0.136	CbGbCtD
Imipramine—SLC22A1—Progesterone—uterine cancer	0.0806	0.118	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0506	0.0743	CbGbCtD
Imipramine—CYP3A7—Progesterone—uterine cancer	0.0506	0.0743	CbGbCtD
Imipramine—CYP2C19—Progesterone—uterine cancer	0.0306	0.045	CbGbCtD
Imipramine—CYP1A2—Progesterone—uterine cancer	0.0283	0.0415	CbGbCtD
Imipramine—ABCB1—Progesterone—uterine cancer	0.0247	0.0363	CbGbCtD
Imipramine—CYP2D6—Progesterone—uterine cancer	0.0233	0.0342	CbGbCtD
Imipramine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0223	0.0328	CbGbCtD
Imipramine—CYP2E1—Etoposide—uterine cancer	0.0219	0.0321	CbGbCtD
Imipramine—ABCB1—Dactinomycin—uterine cancer	0.0196	0.0288	CbGbCtD
Imipramine—CYP3A4—Progesterone—uterine cancer	0.0148	0.0217	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—uterine cancer	0.0147	0.0216	CbGbCtD
Imipramine—CYP1A2—Etoposide—uterine cancer	0.0126	0.0186	CbGbCtD
Imipramine—ABCB1—Etoposide—uterine cancer	0.0111	0.0162	CbGbCtD
Imipramine—CHRM3—ureter—uterine cancer	0.009	0.101	CbGeAlD
Imipramine—ABCB1—Doxorubicin—uterine cancer	0.00754	0.0111	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—uterine cancer	0.00711	0.0104	CbGbCtD
Imipramine—CYP3A4—Etoposide—uterine cancer	0.00662	0.00972	CbGbCtD
Imipramine—CHRM3—muscle of abdomen—uterine cancer	0.00648	0.0729	CbGeAlD
Imipramine—CYP3A4—Doxorubicin—uterine cancer	0.00452	0.00663	CbGbCtD
Imipramine—KCND2—myometrium—uterine cancer	0.00271	0.0305	CbGeAlD
Imipramine—KCND2—decidua—uterine cancer	0.00201	0.0226	CbGeAlD
Imipramine—HTR7—artery—uterine cancer	0.00194	0.0218	CbGeAlD
Imipramine—KCND3—uterine cervix—uterine cancer	0.00184	0.0207	CbGeAlD
Imipramine—CHRM3—exocrine gland—uterine cancer	0.00177	0.02	CbGeAlD
Imipramine—CYP2C18—uterine cervix—uterine cancer	0.00167	0.0188	CbGeAlD
Imipramine—KCND3—uterus—uterine cancer	0.00153	0.0172	CbGeAlD
Imipramine—CYP2C18—mammalian vulva—uterine cancer	0.00146	0.0165	CbGeAlD
Imipramine—KCND2—female gonad—uterine cancer	0.00144	0.0162	CbGeAlD
Imipramine—CHRM5—epithelium—uterine cancer	0.00138	0.0155	CbGeAlD
Imipramine—SLC22A4—myometrium—uterine cancer	0.00125	0.014	CbGeAlD
Imipramine—ADRA1D—epithelium—uterine cancer	0.00123	0.0139	CbGeAlD
Imipramine—SLC22A2—renal system—uterine cancer	0.00122	0.0137	CbGeAlD
Imipramine—HTR2A—artery—uterine cancer	0.00121	0.0136	CbGeAlD
Imipramine—ADRA1B—renal system—uterine cancer	0.00117	0.0132	CbGeAlD
Imipramine—CYP2C18—vagina—uterine cancer	0.00113	0.0128	CbGeAlD
Imipramine—SLC22A3—myometrium—uterine cancer	0.00113	0.0127	CbGeAlD
Imipramine—SLC22A4—decidua—uterine cancer	0.000923	0.0104	CbGeAlD
Imipramine—ADRA1D—female reproductive system—uterine cancer	0.000916	0.0103	CbGeAlD
Imipramine—ORM1—endometrium—uterine cancer	0.000911	0.0102	CbGeAlD
Imipramine—SLC22A4—renal system—uterine cancer	0.000906	0.0102	CbGeAlD
Imipramine—SLC22A3—uterine cervix—uterine cancer	0.000882	0.00992	CbGeAlD
Imipramine—SLC22A4—endometrium—uterine cancer	0.000876	0.00986	CbGeAlD
Imipramine—KCNH2—myometrium—uterine cancer	0.000872	0.00981	CbGeAlD
Imipramine—SLC22A1—renal system—uterine cancer	0.000863	0.00971	CbGeAlD
Imipramine—SLC22A3—smooth muscle tissue—uterine cancer	0.000857	0.00964	CbGeAlD
Imipramine—SLC22A3—renal system—uterine cancer	0.000825	0.00928	CbGeAlD
Imipramine—KCND3—lymph node—uterine cancer	0.000805	0.00906	CbGeAlD
Imipramine—SLC22A3—endometrium—uterine cancer	0.000798	0.00897	CbGeAlD
Imipramine—SLC22A3—mammalian vulva—uterine cancer	0.000771	0.00868	CbGeAlD
Imipramine—ORM1—female reproductive system—uterine cancer	0.000755	0.00849	CbGeAlD
Imipramine—CHRM3—smooth muscle tissue—uterine cancer	0.000744	0.00836	CbGeAlD
Imipramine—HTR7—epithelium—uterine cancer	0.000735	0.00826	CbGeAlD
Imipramine—SLC22A4—female reproductive system—uterine cancer	0.000726	0.00817	CbGeAlD
Imipramine—SLC6A2—decidua—uterine cancer	0.00072	0.0081	CbGeAlD
Imipramine—CHRM3—renal system—uterine cancer	0.000716	0.00805	CbGeAlD
Imipramine—HTR1A—renal system—uterine cancer	0.000713	0.00802	CbGeAlD
Imipramine—ADRA1A—epithelium—uterine cancer	0.000708	0.00797	CbGeAlD
Imipramine—HTR7—smooth muscle tissue—uterine cancer	0.000708	0.00796	CbGeAlD
Imipramine—HRH1—myometrium—uterine cancer	0.000699	0.00786	CbGeAlD
Imipramine—HTR7—renal system—uterine cancer	0.000681	0.00766	CbGeAlD
Imipramine—KCNH2—uterine cervix—uterine cancer	0.000678	0.00763	CbGeAlD
Imipramine—HTR2C—female reproductive system—uterine cancer	0.000678	0.00763	CbGeAlD
Imipramine—SLC22A3—female reproductive system—uterine cancer	0.000661	0.00743	CbGeAlD
Imipramine—ADRA1A—renal system—uterine cancer	0.000657	0.00739	CbGeAlD
Imipramine—SLC22A4—vagina—uterine cancer	0.000657	0.00738	CbGeAlD
Imipramine—SLC6A4—female reproductive system—uterine cancer	0.000643	0.00723	CbGeAlD
Imipramine—CHRM1—female reproductive system—uterine cancer	0.000641	0.0072	CbGeAlD
Imipramine—KCNH2—renal system—uterine cancer	0.000635	0.00714	CbGeAlD
Imipramine—SLC22A1—vagina—uterine cancer	0.000625	0.00703	CbGeAlD
Imipramine—KCNH2—endometrium—uterine cancer	0.000614	0.0069	CbGeAlD
Imipramine—SLC22A3—female gonad—uterine cancer	0.000601	0.00676	CbGeAlD
Imipramine—SLC22A3—vagina—uterine cancer	0.000598	0.00672	CbGeAlD
Imipramine—CHRM3—female reproductive system—uterine cancer	0.000573	0.00645	CbGeAlD
Imipramine—SLC6A2—female reproductive system—uterine cancer	0.000566	0.00637	CbGeAlD
Imipramine—KCNH2—uterus—uterine cancer	0.000565	0.00636	CbGeAlD
Imipramine—HRH1—epithelium—uterine cancer	0.000548	0.00617	CbGeAlD
Imipramine—HTR7—female reproductive system—uterine cancer	0.000546	0.00614	CbGeAlD
Imipramine—HRH1—uterine cervix—uterine cancer	0.000544	0.00612	CbGeAlD
Imipramine—CYP1A2—renal system—uterine cancer	0.000543	0.00611	CbGeAlD
Imipramine—HRH1—smooth muscle tissue—uterine cancer	0.000528	0.00594	CbGeAlD
Imipramine—CHRM3—female gonad—uterine cancer	0.000522	0.00587	CbGeAlD
Imipramine—CYP2B6—renal system—uterine cancer	0.000521	0.00586	CbGeAlD
Imipramine—HRH1—decidua—uterine cancer	0.000518	0.00583	CbGeAlD
Imipramine—KCNH2—female reproductive system—uterine cancer	0.000508	0.00572	CbGeAlD
Imipramine—HRH1—endometrium—uterine cancer	0.000492	0.00553	CbGeAlD
Imipramine—CYP2E1—renal system—uterine cancer	0.000489	0.0055	CbGeAlD
Imipramine—CYP2C19—vagina—uterine cancer	0.000482	0.00542	CbGeAlD
Imipramine—HRH1—mammalian vulva—uterine cancer	0.000476	0.00535	CbGeAlD
Imipramine—KCNH2—female gonad—uterine cancer	0.000463	0.0052	CbGeAlD
Imipramine—KCNH2—vagina—uterine cancer	0.00046	0.00517	CbGeAlD
Imipramine—HTR2A—epithelium—uterine cancer	0.000458	0.00515	CbGeAlD
Imipramine—ORM1—lymph node—uterine cancer	0.000441	0.00497	CbGeAlD
Imipramine—HTR2A—smooth muscle tissue—uterine cancer	0.000441	0.00496	CbGeAlD
Imipramine—HTR2A—renal system—uterine cancer	0.000425	0.00478	CbGeAlD
Imipramine—SLC22A4—lymph node—uterine cancer	0.000425	0.00478	CbGeAlD
Imipramine—CYP2B6—female reproductive system—uterine cancer	0.000417	0.00469	CbGeAlD
Imipramine—HRH1—female reproductive system—uterine cancer	0.000407	0.00458	CbGeAlD
Imipramine—CYP3A4—renal system—uterine cancer	0.000393	0.00442	CbGeAlD
Imipramine—CYP2E1—female reproductive system—uterine cancer	0.000391	0.0044	CbGeAlD
Imipramine—CYP2D6—renal system—uterine cancer	0.000387	0.00435	CbGeAlD
Imipramine—SLC22A3—lymph node—uterine cancer	0.000386	0.00435	CbGeAlD
Imipramine—ABCB1—myometrium—uterine cancer	0.000382	0.0043	CbGeAlD
Imipramine—CYP2B6—vagina—uterine cancer	0.000377	0.00424	CbGeAlD
Imipramine—HRH1—female gonad—uterine cancer	0.000371	0.00417	CbGeAlD
Imipramine—HRH1—vagina—uterine cancer	0.000368	0.00414	CbGeAlD
Imipramine—HTR2A—female reproductive system—uterine cancer	0.00034	0.00383	CbGeAlD
Imipramine—SLC6A2—lymph node—uterine cancer	0.000331	0.00372	CbGeAlD
Imipramine—Angiopathy—Etoposide—uterine cancer	0.000318	0.00168	CcSEcCtD
Imipramine—Vascular purpura—Epirubicin—uterine cancer	0.000317	0.00167	CcSEcCtD
Imipramine—Immune system disorder—Etoposide—uterine cancer	0.000316	0.00167	CcSEcCtD
Imipramine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000316	0.00167	CcSEcCtD
Imipramine—Mediastinal disorder—Etoposide—uterine cancer	0.000316	0.00166	CcSEcCtD
Imipramine—CYP3A4—female reproductive system—uterine cancer	0.000315	0.00354	CbGeAlD
Imipramine—Cardiac failure congestive—Epirubicin—uterine cancer	0.000313	0.00165	CcSEcCtD
Imipramine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000312	0.00164	CcSEcCtD
Imipramine—CYP2D6—female reproductive system—uterine cancer	0.00031	0.00349	CbGeAlD
Imipramine—Alopecia—Etoposide—uterine cancer	0.000309	0.00163	CcSEcCtD
Imipramine—Vomiting—Progesterone—uterine cancer	0.000309	0.00163	CcSEcCtD
Imipramine—HTR2A—vagina—uterine cancer	0.000308	0.00346	CbGeAlD
Imipramine—Rash—Progesterone—uterine cancer	0.000307	0.00162	CcSEcCtD
Imipramine—Dermatitis—Progesterone—uterine cancer	0.000306	0.00162	CcSEcCtD
Imipramine—Headache—Progesterone—uterine cancer	0.000305	0.00161	CcSEcCtD
Imipramine—Hot flush—Epirubicin—uterine cancer	0.000303	0.0016	CcSEcCtD
Imipramine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000301	0.00159	CcSEcCtD
Imipramine—Menopausal symptoms—Epirubicin—uterine cancer	0.000301	0.00159	CcSEcCtD
Imipramine—ABCB1—epithelium—uterine cancer	0.0003	0.00338	CbGeAlD
Imipramine—Decreased appetite—Dactinomycin—uterine cancer	0.000299	0.00158	CcSEcCtD
Imipramine—Dysgeusia—Etoposide—uterine cancer	0.000298	0.00157	CcSEcCtD
Imipramine—ABCB1—uterine cervix—uterine cancer	0.000298	0.00335	CbGeAlD
Imipramine—KCNH2—lymph node—uterine cancer	0.000297	0.00334	CbGeAlD
Imipramine—Fatigue—Dactinomycin—uterine cancer	0.000296	0.00156	CcSEcCtD
Imipramine—Purpura—Epirubicin—uterine cancer	0.000294	0.00155	CcSEcCtD
Imipramine—Vascular purpura—Doxorubicin—uterine cancer	0.000293	0.00155	CcSEcCtD
Imipramine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000291	0.00154	CcSEcCtD
Imipramine—Cardiac failure—Epirubicin—uterine cancer	0.000291	0.00153	CcSEcCtD
Imipramine—Cerebrovascular accident—Epirubicin—uterine cancer	0.000289	0.00153	CcSEcCtD
Imipramine—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000289	0.00153	CcSEcCtD
Imipramine—Nausea—Progesterone—uterine cancer	0.000289	0.00152	CcSEcCtD
Imipramine—ABCB1—decidua—uterine cancer	0.000284	0.00319	CbGeAlD
Imipramine—Feeling abnormal—Dactinomycin—uterine cancer	0.000283	0.00149	CcSEcCtD
Imipramine—Ill-defined disorder—Etoposide—uterine cancer	0.000283	0.00149	CcSEcCtD
Imipramine—CYP2D6—female gonad—uterine cancer	0.000282	0.00317	CbGeAlD
Imipramine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000281	0.00148	CcSEcCtD
Imipramine—Hot flush—Doxorubicin—uterine cancer	0.000281	0.00148	CcSEcCtD
Imipramine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00028	0.00148	CcSEcCtD
Imipramine—Affect lability—Epirubicin—uterine cancer	0.000279	0.00147	CcSEcCtD
Imipramine—ABCB1—renal system—uterine cancer	0.000278	0.00313	CbGeAlD
Imipramine—Menopausal symptoms—Doxorubicin—uterine cancer	0.000278	0.00147	CcSEcCtD
Imipramine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.00147	CcSEcCtD
Imipramine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.00146	CcSEcCtD
Imipramine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000276	0.00146	CcSEcCtD
Imipramine—Malaise—Etoposide—uterine cancer	0.000275	0.00145	CcSEcCtD
Imipramine—Leukopenia—Etoposide—uterine cancer	0.000273	0.00144	CcSEcCtD
Imipramine—Purpura—Doxorubicin—uterine cancer	0.000272	0.00144	CcSEcCtD
Imipramine—Body temperature increased—Dactinomycin—uterine cancer	0.000272	0.00143	CcSEcCtD
Imipramine—Abdominal pain—Dactinomycin—uterine cancer	0.000272	0.00143	CcSEcCtD
Imipramine—ABCB1—endometrium—uterine cancer	0.000269	0.00303	CbGeAlD
Imipramine—Cardiac failure—Doxorubicin—uterine cancer	0.000269	0.00142	CcSEcCtD
Imipramine—Mood swings—Epirubicin—uterine cancer	0.000269	0.00142	CcSEcCtD
Imipramine—Loss of consciousness—Etoposide—uterine cancer	0.000268	0.00141	CcSEcCtD
Imipramine—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000268	0.00141	CcSEcCtD
Imipramine—Ataxia—Epirubicin—uterine cancer	0.000267	0.00141	CcSEcCtD
Imipramine—Convulsion—Etoposide—uterine cancer	0.000264	0.00139	CcSEcCtD
Imipramine—Hypertension—Etoposide—uterine cancer	0.000263	0.00139	CcSEcCtD
Imipramine—Liver function test abnormal—Epirubicin—uterine cancer	0.000262	0.00138	CcSEcCtD
Imipramine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000262	0.00138	CcSEcCtD
Imipramine—ABCB1—mammalian vulva—uterine cancer	0.00026	0.00293	CbGeAlD
Imipramine—Orthostatic hypotension—Epirubicin—uterine cancer	0.000259	0.00137	CcSEcCtD
Imipramine—Affect lability—Doxorubicin—uterine cancer	0.000258	0.00136	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000258	0.00136	CcSEcCtD
Imipramine—Discomfort—Etoposide—uterine cancer	0.000256	0.00135	CcSEcCtD
Imipramine—Breast disorder—Epirubicin—uterine cancer	0.000256	0.00135	CcSEcCtD
Imipramine—Confusional state—Etoposide—uterine cancer	0.000251	0.00132	CcSEcCtD
Imipramine—Anaphylactic shock—Etoposide—uterine cancer	0.000249	0.00131	CcSEcCtD
Imipramine—Mood swings—Doxorubicin—uterine cancer	0.000249	0.00131	CcSEcCtD
Imipramine—ABCB1—uterus—uterine cancer	0.000248	0.00279	CbGeAlD
Imipramine—Infection—Etoposide—uterine cancer	0.000247	0.0013	CcSEcCtD
Imipramine—Ataxia—Doxorubicin—uterine cancer	0.000247	0.0013	CcSEcCtD
Imipramine—Asthenia—Dactinomycin—uterine cancer	0.000247	0.0013	CcSEcCtD
Imipramine—Thrombocytopenia—Etoposide—uterine cancer	0.000244	0.00128	CcSEcCtD
Imipramine—Tachycardia—Etoposide—uterine cancer	0.000243	0.00128	CcSEcCtD
Imipramine—Eosinophilia—Epirubicin—uterine cancer	0.000243	0.00128	CcSEcCtD
Imipramine—Liver function test abnormal—Doxorubicin—uterine cancer	0.000242	0.00128	CcSEcCtD
Imipramine—Skin disorder—Etoposide—uterine cancer	0.000242	0.00127	CcSEcCtD
Imipramine—Hyperhidrosis—Etoposide—uterine cancer	0.00024	0.00127	CcSEcCtD
Imipramine—Orthostatic hypotension—Doxorubicin—uterine cancer	0.00024	0.00126	CcSEcCtD
Imipramine—HRH1—lymph node—uterine cancer	0.000238	0.00268	CbGeAlD
Imipramine—Breast disorder—Doxorubicin—uterine cancer	0.000237	0.00125	CcSEcCtD
Imipramine—Anorexia—Etoposide—uterine cancer	0.000237	0.00125	CcSEcCtD
Imipramine—Diarrhoea—Dactinomycin—uterine cancer	0.000235	0.00124	CcSEcCtD
Imipramine—Pancytopenia—Epirubicin—uterine cancer	0.000233	0.00123	CcSEcCtD
Imipramine—Pollakiuria—Epirubicin—uterine cancer	0.000226	0.00119	CcSEcCtD
Imipramine—Eosinophilia—Doxorubicin—uterine cancer	0.000225	0.00118	CcSEcCtD
Imipramine—Photosensitivity reaction—Epirubicin—uterine cancer	0.000224	0.00118	CcSEcCtD
Imipramine—Paraesthesia—Etoposide—uterine cancer	0.000223	0.00118	CcSEcCtD
Imipramine—Weight increased—Epirubicin—uterine cancer	0.000223	0.00118	CcSEcCtD
Imipramine—ABCB1—female reproductive system—uterine cancer	0.000223	0.00251	CbGeAlD
Imipramine—Weight decreased—Epirubicin—uterine cancer	0.000222	0.00117	CcSEcCtD
Imipramine—Somnolence—Etoposide—uterine cancer	0.000221	0.00117	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—uterine cancer	0.000219	0.00115	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—uterine cancer	0.000219	0.00115	CcSEcCtD
Imipramine—Infestation—Epirubicin—uterine cancer	0.000219	0.00115	CcSEcCtD
Imipramine—Vomiting—Dactinomycin—uterine cancer	0.000218	0.00115	CcSEcCtD
Imipramine—Rash—Dactinomycin—uterine cancer	0.000217	0.00114	CcSEcCtD
Imipramine—Decreased appetite—Etoposide—uterine cancer	0.000216	0.00114	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—uterine cancer	0.000215	0.00114	CcSEcCtD
Imipramine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000215	0.00113	CcSEcCtD
Imipramine—Fatigue—Etoposide—uterine cancer	0.000214	0.00113	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000214	0.00113	CcSEcCtD
Imipramine—Jaundice—Epirubicin—uterine cancer	0.000213	0.00112	CcSEcCtD
Imipramine—Stomatitis—Epirubicin—uterine cancer	0.000213	0.00112	CcSEcCtD
Imipramine—Constipation—Etoposide—uterine cancer	0.000213	0.00112	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—uterine cancer	0.00021	0.00111	CcSEcCtD
Imipramine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000207	0.00109	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000207	0.00109	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—uterine cancer	0.000206	0.00109	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—uterine cancer	0.000205	0.00108	CcSEcCtD
Imipramine—Feeling abnormal—Etoposide—uterine cancer	0.000205	0.00108	CcSEcCtD
Imipramine—Nausea—Dactinomycin—uterine cancer	0.000204	0.00108	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—uterine cancer	0.000204	0.00108	CcSEcCtD
Imipramine—Gastrointestinal pain—Etoposide—uterine cancer	0.000203	0.00107	CcSEcCtD
Imipramine—ABCB1—female gonad—uterine cancer	0.000203	0.00228	CbGeAlD
Imipramine—Drowsiness—Doxorubicin—uterine cancer	0.000202	0.00107	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—uterine cancer	0.000202	0.00107	CcSEcCtD
Imipramine—Infestation—Doxorubicin—uterine cancer	0.000202	0.00107	CcSEcCtD
Imipramine—ABCB1—vagina—uterine cancer	0.000202	0.00227	CbGeAlD
Imipramine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000198	0.00105	CcSEcCtD
Imipramine—Urticaria—Etoposide—uterine cancer	0.000198	0.00104	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—uterine cancer	0.000197	0.00104	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—uterine cancer	0.000197	0.00104	CcSEcCtD
Imipramine—Abdominal pain—Etoposide—uterine cancer	0.000197	0.00104	CcSEcCtD
Imipramine—Body temperature increased—Etoposide—uterine cancer	0.000197	0.00104	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—uterine cancer	0.000196	0.00103	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—uterine cancer	0.000195	0.00103	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—uterine cancer	0.000194	0.00102	CcSEcCtD
Imipramine—Urethral disorder—Epirubicin—uterine cancer	0.000192	0.00101	CcSEcCtD
Imipramine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000191	0.00101	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—uterine cancer	0.000189	0.000995	CcSEcCtD
Imipramine—Eye disorder—Epirubicin—uterine cancer	0.000183	0.000967	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—uterine cancer	0.000183	0.000965	CcSEcCtD
Imipramine—Flushing—Epirubicin—uterine cancer	0.000182	0.000961	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—uterine cancer	0.000182	0.000961	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—uterine cancer	0.000182	0.000958	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—uterine cancer	0.000181	0.000953	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—uterine cancer	0.000179	0.000946	CcSEcCtD
Imipramine—Asthenia—Etoposide—uterine cancer	0.000178	0.000941	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—uterine cancer	0.000178	0.000939	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—uterine cancer	0.000178	0.000939	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—uterine cancer	0.000177	0.000935	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—uterine cancer	0.000177	0.000933	CcSEcCtD
Imipramine—Pruritus—Etoposide—uterine cancer	0.000176	0.000928	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—uterine cancer	0.000175	0.000925	CcSEcCtD
Imipramine—Alopecia—Epirubicin—uterine cancer	0.000173	0.000915	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—uterine cancer	0.000172	0.000907	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—uterine cancer	0.000171	0.000901	CcSEcCtD
Imipramine—Diarrhoea—Etoposide—uterine cancer	0.00017	0.000898	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—uterine cancer	0.00017	0.000895	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—uterine cancer	0.000169	0.000893	CcSEcCtD
Imipramine—Flushing—Doxorubicin—uterine cancer	0.000169	0.000889	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—uterine cancer	0.000169	0.000889	CcSEcCtD
Imipramine—Tension—Epirubicin—uterine cancer	0.000168	0.000884	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—uterine cancer	0.000167	0.000882	CcSEcCtD
Imipramine—Nervousness—Epirubicin—uterine cancer	0.000166	0.000875	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—uterine cancer	0.000165	0.000869	CcSEcCtD
Imipramine—Dizziness—Etoposide—uterine cancer	0.000164	0.000867	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—uterine cancer	0.000164	0.000865	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000164	0.000863	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—uterine cancer	0.000162	0.000855	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—uterine cancer	0.000161	0.000849	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—uterine cancer	0.00016	0.000846	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—uterine cancer	0.000159	0.000839	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—uterine cancer	0.000159	0.000836	CcSEcCtD
Imipramine—Vomiting—Etoposide—uterine cancer	0.000158	0.000834	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—uterine cancer	0.000158	0.000834	CcSEcCtD
Imipramine—Agitation—Epirubicin—uterine cancer	0.000157	0.000828	CcSEcCtD
Imipramine—Rash—Etoposide—uterine cancer	0.000157	0.000827	CcSEcCtD
Imipramine—Dermatitis—Etoposide—uterine cancer	0.000157	0.000826	CcSEcCtD
Imipramine—Headache—Etoposide—uterine cancer	0.000156	0.000822	CcSEcCtD
Imipramine—Tension—Doxorubicin—uterine cancer	0.000155	0.000818	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—uterine cancer	0.000155	0.000816	CcSEcCtD
Imipramine—Malaise—Epirubicin—uterine cancer	0.000154	0.000812	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—uterine cancer	0.000154	0.00081	CcSEcCtD
Imipramine—Syncope—Epirubicin—uterine cancer	0.000153	0.000808	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—uterine cancer	0.000153	0.000806	CcSEcCtD
Imipramine—Palpitations—Epirubicin—uterine cancer	0.000151	0.000796	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—uterine cancer	0.00015	0.000792	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—uterine cancer	0.000149	0.000786	CcSEcCtD
Imipramine—Convulsion—Epirubicin—uterine cancer	0.000148	0.000781	CcSEcCtD
Imipramine—Nausea—Etoposide—uterine cancer	0.000148	0.000779	CcSEcCtD
Imipramine—Hypertension—Epirubicin—uterine cancer	0.000147	0.000778	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000147	0.000773	CcSEcCtD
Imipramine—Agitation—Doxorubicin—uterine cancer	0.000145	0.000766	CcSEcCtD
Imipramine—Anxiety—Epirubicin—uterine cancer	0.000145	0.000764	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000144	0.000762	CcSEcCtD
Imipramine—Discomfort—Epirubicin—uterine cancer	0.000144	0.000758	CcSEcCtD
Imipramine—Malaise—Doxorubicin—uterine cancer	0.000143	0.000752	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—uterine cancer	0.000142	0.00075	CcSEcCtD
Imipramine—Syncope—Doxorubicin—uterine cancer	0.000142	0.000748	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—uterine cancer	0.000141	0.000746	CcSEcCtD
Imipramine—Confusional state—Epirubicin—uterine cancer	0.000141	0.000741	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—uterine cancer	0.00014	0.000737	CcSEcCtD
Imipramine—Oedema—Epirubicin—uterine cancer	0.000139	0.000735	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—uterine cancer	0.000139	0.000735	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—uterine cancer	0.000139	0.000733	CcSEcCtD
Imipramine—Infection—Epirubicin—uterine cancer	0.000139	0.00073	CcSEcCtD
Imipramine—Shock—Epirubicin—uterine cancer	0.000137	0.000723	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—uterine cancer	0.000137	0.000722	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—uterine cancer	0.000137	0.000721	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—uterine cancer	0.000137	0.00072	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—uterine cancer	0.000136	0.00072	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—uterine cancer	0.000136	0.000718	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—uterine cancer	0.000135	0.000714	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—uterine cancer	0.000135	0.000711	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—uterine cancer	0.000134	0.000707	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000134	0.000705	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—uterine cancer	0.000133	0.000701	CcSEcCtD
Imipramine—Anorexia—Epirubicin—uterine cancer	0.000133	0.000701	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—uterine cancer	0.000132	0.000694	CcSEcCtD
Imipramine—ABCB1—lymph node—uterine cancer	0.00013	0.00147	CbGeAlD
Imipramine—Confusional state—Doxorubicin—uterine cancer	0.00013	0.000686	CcSEcCtD
Imipramine—Oedema—Doxorubicin—uterine cancer	0.000129	0.00068	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—uterine cancer	0.000129	0.00068	CcSEcCtD
Imipramine—Infection—Doxorubicin—uterine cancer	0.000128	0.000676	CcSEcCtD
Imipramine—Shock—Doxorubicin—uterine cancer	0.000127	0.000669	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—uterine cancer	0.000127	0.000667	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000126	0.000666	CcSEcCtD
Imipramine—Insomnia—Epirubicin—uterine cancer	0.000126	0.000665	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—uterine cancer	0.000126	0.000664	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—uterine cancer	0.000125	0.000661	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—uterine cancer	0.000125	0.00066	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000125	0.000658	CcSEcCtD
Imipramine—Somnolence—Epirubicin—uterine cancer	0.000124	0.000654	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—uterine cancer	0.000123	0.000649	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—uterine cancer	0.000123	0.000647	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—uterine cancer	0.000121	0.000639	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00012	0.000635	CcSEcCtD
Imipramine—Fatigue—Epirubicin—uterine cancer	0.00012	0.000634	CcSEcCtD
Imipramine—Constipation—Epirubicin—uterine cancer	0.000119	0.000629	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—uterine cancer	0.000117	0.000615	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—uterine cancer	0.000116	0.000611	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—uterine cancer	0.000115	0.000606	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—uterine cancer	0.000115	0.000605	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000114	0.000601	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—uterine cancer	0.000114	0.000599	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—uterine cancer	0.000112	0.000591	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000111	0.000587	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—uterine cancer	0.000111	0.000587	CcSEcCtD
Imipramine—Urticaria—Epirubicin—uterine cancer	0.000111	0.000584	CcSEcCtD
Imipramine—Constipation—Doxorubicin—uterine cancer	0.00011	0.000582	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—uterine cancer	0.00011	0.000581	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—uterine cancer	0.00011	0.000581	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—uterine cancer	0.000106	0.000561	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000105	0.000556	CcSEcCtD
Imipramine—Urticaria—Doxorubicin—uterine cancer	0.000102	0.00054	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—uterine cancer	0.000102	0.000538	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—uterine cancer	0.000102	0.000538	CcSEcCtD
Imipramine—Asthenia—Epirubicin—uterine cancer	0.0001	0.000528	CcSEcCtD
Imipramine—Pruritus—Epirubicin—uterine cancer	9.86e-05	0.00052	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—uterine cancer	9.54e-05	0.000503	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—uterine cancer	9.26e-05	0.000488	CcSEcCtD
Imipramine—Dizziness—Epirubicin—uterine cancer	9.22e-05	0.000486	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—uterine cancer	9.13e-05	0.000481	CcSEcCtD
Imipramine—Vomiting—Epirubicin—uterine cancer	8.86e-05	0.000468	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—uterine cancer	8.83e-05	0.000466	CcSEcCtD
Imipramine—Rash—Epirubicin—uterine cancer	8.79e-05	0.000464	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—uterine cancer	8.78e-05	0.000463	CcSEcCtD
Imipramine—Headache—Epirubicin—uterine cancer	8.73e-05	0.000461	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—uterine cancer	8.53e-05	0.00045	CcSEcCtD
Imipramine—Nausea—Epirubicin—uterine cancer	8.28e-05	0.000437	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—uterine cancer	8.2e-05	0.000433	CcSEcCtD
Imipramine—Rash—Doxorubicin—uterine cancer	8.13e-05	0.000429	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—uterine cancer	8.13e-05	0.000429	CcSEcCtD
Imipramine—Headache—Doxorubicin—uterine cancer	8.08e-05	0.000426	CcSEcCtD
Imipramine—Nausea—Doxorubicin—uterine cancer	7.66e-05	0.000404	CcSEcCtD
Imipramine—Benazepril—MTHFR—uterine cancer	3.86e-05	1	CrCbGaD
Imipramine—ADRA1B—Signaling Pathways—ERBB2—uterine cancer	4.45e-06	0.000111	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—PIK3CA—uterine cancer	4.45e-06	0.00011	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—KRAS—uterine cancer	4.44e-06	0.00011	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—PIK3CA—uterine cancer	4.44e-06	0.00011	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CXCL8—uterine cancer	4.43e-06	0.00011	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.43e-06	0.00011	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTEN—uterine cancer	4.42e-06	0.00011	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CXCL8—uterine cancer	4.41e-06	0.000109	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—HRAS—uterine cancer	4.41e-06	0.000109	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—KRAS—uterine cancer	4.4e-06	0.000109	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—VEGFA—uterine cancer	4.4e-06	0.000109	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—MTHFR—uterine cancer	4.39e-06	0.000109	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—KRAS—uterine cancer	4.38e-06	0.000109	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—HRAS—uterine cancer	4.38e-06	0.000109	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EP300—uterine cancer	4.36e-06	0.000108	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—AKT1—uterine cancer	4.36e-06	0.000108	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—NRAS—uterine cancer	4.34e-06	0.000108	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CDKN1B—uterine cancer	4.33e-06	0.000107	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CDKN1B—uterine cancer	4.31e-06	0.000107	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—AKT1—uterine cancer	4.28e-06	0.000106	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—AKT1—uterine cancer	4.26e-06	0.000106	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CXCL8—uterine cancer	4.22e-06	0.000105	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—EP300—uterine cancer	4.22e-06	0.000105	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.21e-06	0.000104	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—HRAS—uterine cancer	4.2e-06	0.000104	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	4.18e-06	0.000104	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KRAS—uterine cancer	4.14e-06	0.000103	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—VEGFA—uterine cancer	4.13e-06	0.000103	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KRAS—uterine cancer	4.13e-06	0.000103	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CDKN1B—uterine cancer	4.12e-06	0.000102	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—AKT1—uterine cancer	4.12e-06	0.000102	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—PIK3CA—uterine cancer	4.11e-06	0.000102	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—ERBB2—uterine cancer	4.11e-06	0.000102	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—PIK3CA—uterine cancer	4.11e-06	0.000102	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—PIK3CA—uterine cancer	4.09e-06	0.000102	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CTNNB1—uterine cancer	4.09e-06	0.000102	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTEN—uterine cancer	4.08e-06	0.000101	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—NRAS—uterine cancer	4.08e-06	0.000101	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—AKT1—uterine cancer	4.08e-06	0.000101	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—PIK3CA—uterine cancer	4.08e-06	0.000101	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CTNNB1—uterine cancer	4.07e-06	0.000101	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—ERBB2—uterine cancer	4.04e-06	0.0001	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—PIK3CA—uterine cancer	4.04e-06	0.0001	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—ERBB2—uterine cancer	4.03e-06	0.0001	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—PIK3CA—uterine cancer	4.03e-06	0.0001	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—ERBB2—uterine cancer	4.02e-06	9.97e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—ERBB2—uterine cancer	4.01e-06	9.94e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PTEN—uterine cancer	3.99e-06	9.9e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PTEN—uterine cancer	3.97e-06	9.84e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—ERBB2—uterine cancer	3.97e-06	9.84e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	3.96e-06	9.82e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KRAS—uterine cancer	3.9e-06	9.68e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CTNNB1—uterine cancer	3.9e-06	9.67e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—EP300—uterine cancer	3.9e-06	9.67e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CXCL8—uterine cancer	3.89e-06	9.66e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—AKT1—uterine cancer	3.89e-06	9.65e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—AKT1—uterine cancer	3.87e-06	9.6e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—HRAS—uterine cancer	3.87e-06	9.6e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CXCL8—uterine cancer	3.83e-06	9.51e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CXCL8—uterine cancer	3.82e-06	9.49e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—STK11—uterine cancer	3.82e-06	9.48e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.82e-06	9.48e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CXCL8—uterine cancer	3.81e-06	9.46e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—HRAS—uterine cancer	3.81e-06	9.45e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EP300—uterine cancer	3.8e-06	9.44e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CDKN1B—uterine cancer	3.8e-06	9.44e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—PIK3CA—uterine cancer	3.8e-06	9.43e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CXCL8—uterine cancer	3.8e-06	9.43e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—HRAS—uterine cancer	3.8e-06	9.42e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PTEN—uterine cancer	3.8e-06	9.42e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—PIK3CA—uterine cancer	3.8e-06	9.42e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—HRAS—uterine cancer	3.79e-06	9.39e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EP300—uterine cancer	3.78e-06	9.39e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—HRAS—uterine cancer	3.77e-06	9.36e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CXCL8—uterine cancer	3.76e-06	9.33e-05	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—AKT1—uterine cancer	3.76e-06	9.33e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	3.75e-06	9.31e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	3.74e-06	9.28e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—uterine cancer	3.74e-06	9.27e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KRAS—uterine cancer	3.74e-06	9.27e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CDKN1B—uterine cancer	3.73e-06	9.26e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	3.73e-06	9.25e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	3.72e-06	9.23e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—MTHFR—uterine cancer	3.72e-06	9.23e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CDKN1B—uterine cancer	3.71e-06	9.2e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—AKT1—uterine cancer	3.7e-06	9.19e-05	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	3.7e-06	9.18e-05	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—AKT1—uterine cancer	3.69e-06	9.16e-05	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	3.68e-06	9.13e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—uterine cancer	3.68e-06	9.12e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CDKN1B—uterine cancer	3.67e-06	9.12e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—uterine cancer	3.67e-06	9.11e-05	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—AKT1—uterine cancer	3.67e-06	9.11e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	3.66e-06	9.09e-05	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—AKT1—uterine cancer	3.63e-06	9.02e-05	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	3.62e-06	8.99e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EP300—uterine cancer	3.62e-06	8.99e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—uterine cancer	3.6e-06	8.94e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CTNNB1—uterine cancer	3.59e-06	8.91e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—PIK3CA—uterine cancer	3.59e-06	8.9e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—uterine cancer	3.58e-06	8.89e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—NRAS—uterine cancer	3.56e-06	8.83e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NRAS—uterine cancer	3.54e-06	8.78e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	3.53e-06	8.77e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CTNNB1—uterine cancer	3.53e-06	8.75e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—uterine cancer	3.52e-06	8.73e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	3.52e-06	8.72e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—uterine cancer	3.51e-06	8.72e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—uterine cancer	3.51e-06	8.72e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—uterine cancer	3.51e-06	8.72e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CTNNB1—uterine cancer	3.5e-06	8.7e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—uterine cancer	3.5e-06	8.69e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CTNNB1—uterine cancer	3.47e-06	8.61e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—uterine cancer	3.47e-06	8.61e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	3.46e-06	8.59e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—uterine cancer	3.45e-06	8.55e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—uterine cancer	3.44e-06	8.54e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—uterine cancer	3.44e-06	8.53e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PIK3CA—uterine cancer	3.43e-06	8.52e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—uterine cancer	3.43e-06	8.51e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—uterine cancer	3.43e-06	8.5e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—uterine cancer	3.42e-06	8.48e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—uterine cancer	3.42e-06	8.48e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—uterine cancer	3.39e-06	8.41e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—uterine cancer	3.38e-06	8.39e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—uterine cancer	3.37e-06	8.37e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—uterine cancer	3.36e-06	8.34e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—uterine cancer	3.35e-06	8.32e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PIK3CA—uterine cancer	3.35e-06	8.32e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—EP300—uterine cancer	3.35e-06	8.32e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PIK3CA—uterine cancer	3.35e-06	8.31e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—uterine cancer	3.34e-06	8.3e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EP300—uterine cancer	3.34e-06	8.29e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—uterine cancer	3.33e-06	8.27e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—uterine cancer	3.32e-06	8.24e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—uterine cancer	3.32e-06	8.23e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—uterine cancer	3.3e-06	8.19e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	3.29e-06	8.17e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EP300—uterine cancer	3.29e-06	8.15e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—EP300—uterine cancer	3.28e-06	8.15e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EP300—uterine cancer	3.28e-06	8.13e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.28e-06	8.13e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EP300—uterine cancer	3.27e-06	8.11e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EP300—uterine cancer	3.26e-06	8.08e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PIK3CA—uterine cancer	3.23e-06	8.01e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EP300—uterine cancer	3.23e-06	8e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EP300—uterine cancer	3.22e-06	7.98e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—uterine cancer	3.18e-06	7.88e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—uterine cancer	3.16e-06	7.85e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—uterine cancer	3.12e-06	7.75e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—uterine cancer	3.12e-06	7.75e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PIK3CA—uterine cancer	3.12e-06	7.74e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—uterine cancer	3.11e-06	7.72e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—uterine cancer	3.1e-06	7.7e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—uterine cancer	3.1e-06	7.7e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—uterine cancer	3.1e-06	7.7e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—uterine cancer	3.1e-06	7.68e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—uterine cancer	3.09e-06	7.66e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—uterine cancer	3.07e-06	7.63e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—uterine cancer	3.07e-06	7.61e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—uterine cancer	3.06e-06	7.6e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—uterine cancer	3.06e-06	7.59e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—uterine cancer	3.06e-06	7.58e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—uterine cancer	3.05e-06	7.56e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	3.05e-06	7.56e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—uterine cancer	3.05e-06	7.56e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—uterine cancer	3.02e-06	7.49e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—uterine cancer	3.01e-06	7.47e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—uterine cancer	2.99e-06	7.41e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—uterine cancer	2.93e-06	7.27e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—uterine cancer	2.92e-06	7.24e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PIK3CA—uterine cancer	2.88e-06	7.15e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—MTHFR—uterine cancer	2.87e-06	7.12e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	2.81e-06	6.98e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—uterine cancer	2.8e-06	6.96e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	2.8e-06	6.94e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—uterine cancer	2.74e-06	6.8e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—uterine cancer	2.73e-06	6.78e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—uterine cancer	2.72e-06	6.75e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—uterine cancer	2.71e-06	6.72e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—uterine cancer	2.69e-06	6.67e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PIK3CA—uterine cancer	2.68e-06	6.65e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—uterine cancer	2.66e-06	6.59e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—uterine cancer	2.65e-06	6.56e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—uterine cancer	2.64e-06	6.55e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—uterine cancer	2.64e-06	6.54e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—uterine cancer	2.63e-06	6.53e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—uterine cancer	2.62e-06	6.51e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—uterine cancer	2.6e-06	6.46e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—uterine cancer	2.6e-06	6.45e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—uterine cancer	2.59e-06	6.43e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—uterine cancer	2.59e-06	6.43e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—uterine cancer	2.59e-06	6.43e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—uterine cancer	2.59e-06	6.43e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—uterine cancer	2.55e-06	6.32e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—EP300—uterine cancer	2.53e-06	6.28e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PIK3CA—uterine cancer	2.48e-06	6.15e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—uterine cancer	2.48e-06	6.15e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—EP300—uterine cancer	2.47e-06	6.13e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PIK3CA—uterine cancer	2.47e-06	6.13e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—uterine cancer	2.44e-06	6.06e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	2.43e-06	6.03e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PIK3CA—uterine cancer	2.43e-06	6.03e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PIK3CA—uterine cancer	2.43e-06	6.02e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	2.42e-06	6e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PIK3CA—uterine cancer	2.41e-06	5.98e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—uterine cancer	2.39e-06	5.93e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PIK3CA—uterine cancer	2.39e-06	5.92e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	2.38e-06	5.91e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—uterine cancer	2.35e-06	5.84e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—uterine cancer	2.35e-06	5.83e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—uterine cancer	2.35e-06	5.82e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—uterine cancer	2.34e-06	5.8e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—uterine cancer	2.33e-06	5.78e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—EP300—uterine cancer	2.33e-06	5.78e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—uterine cancer	2.31e-06	5.73e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—uterine cancer	2.3e-06	5.71e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—uterine cancer	2.3e-06	5.7e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—uterine cancer	2.29e-06	5.67e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—uterine cancer	2.29e-06	5.67e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—uterine cancer	2.25e-06	5.58e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—uterine cancer	2.24e-06	5.57e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—uterine cancer	2.24e-06	5.55e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—uterine cancer	2.23e-06	5.53e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—uterine cancer	2.21e-06	5.48e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—uterine cancer	2.2e-06	5.46e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—uterine cancer	2.19e-06	5.43e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—uterine cancer	2.07e-06	5.13e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—uterine cancer	2.03e-06	5.03e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—uterine cancer	2.02e-06	5.01e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—uterine cancer	1.99e-06	4.93e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—uterine cancer	1.98e-06	4.92e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—uterine cancer	1.98e-06	4.92e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—uterine cancer	1.97e-06	4.9e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—EP300—uterine cancer	1.97e-06	4.9e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—uterine cancer	1.97e-06	4.88e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—uterine cancer	1.95e-06	4.84e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—uterine cancer	1.94e-06	4.82e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.87e-06	4.65e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CA—uterine cancer	1.83e-06	4.54e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.72e-06	4.28e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—uterine cancer	1.6e-06	3.96e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—uterine cancer	1.53e-06	3.8e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—EP300—uterine cancer	1.52e-06	3.78e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—uterine cancer	1.49e-06	3.71e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.46e-06	3.62e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—uterine cancer	1.41e-06	3.49e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—uterine cancer	1.19e-06	2.96e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.13e-06	2.8e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—uterine cancer	9.2e-07	2.28e-05	CbGpPWpGaD
